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Abstract
We studied major histocompatibility complex (MHC) class I peptide-presentation and nature of the antigen-specific CD8+ T-
cell response from South African tuberculosis (TB) patients with active TB. 361 MHC class I binding epitopes were identified
from three immunogenic TB proteins (ESAT-6 [Rv3875], Ag85B [Rv1886c], and TB10.4 [Rv0288], including amino acid
variations for Rv0288, i.e., A10T, G13D, S27N, and A71S for MHC allotypes common in a South African population (e.g.,
human leukocyte antigen [HLA]-A*30, B*58, and C*07). Inter-allelic differences were identified regarding the broadness of
the peptide-binding capacity. Mapping of frequencies of Mycobacterium tuberculosis (M. tb) antigen-specific CD8+ T-cells
using 48 different multimers, including the newly constructed recombinant MHC class I alleles HLA-B*58:01 and C*0701,
revealed a low frequency of CD8+ T-cell responses directed against a broad panel of co-dominant M. tb epitopes in the
peripheral circulation of most patients. The antigen-specific responses were dominated by CD8+ T-cells with a precursor-like
phenotype (CD45RA+CCR7+). The data show that the CD8+ T-cell response from patients with pulmonary TB (prior to
treatment) is directed against subdominant epitopes derived from secreted and non-secreted M. tb antigens and that
variant, natural occurring M. tb Rv0288 ligands, have a profound impact on T-cell recognition.
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Introduction
8.8 million incident tuberculosis (TB) cases and 1.45 million
TB-related deaths were reported in 2010, with the highest TB
rates occurring in sub-Saharan Africa [1]. The clinical outcome
and presentation of TB is shaped by the interaction of
Mycobacterium tuberculosis (M. tb) genetics and the host’s immuno-
logical response [2].
CD8+ T-cells contribute to the cellular immune defense against
TB [3] early during M. tb infection [4]. Activation and expansion
of M. tb-specific and Major histocompatibility complex (MHC)
class I restricted CD8+ T-cells requires the intracellular processing
of M. tb antigens and subsequent presentation of epitopes by MHC
class I cell-peptide complexes on the cell surface of antigen
presenting cells. The immunogenicity of an M. tb epitope is
influenced by several factors: i) the epitope must be generated and
transported to the endoplasmic reticulum, by overcoming limita-
tions in; cross-presentation [5] proteasome-dependent proteolysis
[6] and the transporter associated with antigen processing [7]; ii)
the epitope must bind to the MHC haplotype with appropriate
affinity and dissociation rate; iii) the peptide-MHC (p-MHC)
complex must then be recognized by an appropriate T-cell
receptor (TCR) repertoire.
In order to determine immunogenicity of selected candidate M.
tb epitopes, it is vital to correlate peptide MHC-binding to the
actual detection of antigen-specific T-cells without in vitro
manipulation (i.e. using in vitro expansion). This can be achieved
in an unbiased way using MHC class I multimers loaded with
molecularly defined pathogen-derived epitopes [8].
A marked heterogeneity characterizes the human immune-
response against M. tb; the host-pathogen interplay dictates the
outcome of infection. Different clustering of MHC alleles, human
leukocyte antigens (HLA), are associated with geographic locations
or ethnicity [9]. This association may, in part, reflect local host-
pathogen co-adaptation which has driven both MHC and
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58309
pathogen diversification. Differences in ethnicity and MHC alleles
have previously been shown to play a role in T-cell responses to a
number of infectious diseases, e.g. Hepatitis B [10], Hepatitis C
[11] and human immunodeficiency virus (HIV) [12]. Associations
between the host populations and defined lineages of M. tb have
previously been identified [13,14], therefore we chose to study the
impact of different host (MHC class I alleles) and pathogen (strain-
to-strain epitope) variations on M. tb peptide presentation on three
levels: 1) peptide-MHC association, 2) TCR-recognition and 3)
phenotype and cytotoxicity of CD8+ antigen-specific T-cells
directed against different M. tb target antigens.
Up until now, only a few M. tb T-cell epitopes, restricted by a
limited number of MHC class I alleles have been identified [15].
Therefore, there is a great need to identify additional M. tb
epitopes restricted by a more diverse MHC class I allelic repertoire
that reflects ethnical populations in Africa. In many regions of sub-
Saharan Africa including South Africa, the most common HLA-A
molecules are A*02, A*23, A*30 and A*68, the most common
HLA-B alleles are B*15, B*42, B*53 and B*58 and the most
common HLA*C alleles are C*04, C*06, C*07 and C*17 [16,17],
alleles for which only very few M. tb epitopes have previously been
defined [15,17].
Not only the MHC class I alleles show diversity, also the
pathogen shows variations. It was previously thought that the M. tb
genome is relatively stable, however an increasing number of
strain-to strain differences, i.e. insertions, deletions and point
mutations in the M. tb genome have been observed [18]. This
genetic diversity might have both phenotypical and immunological
impacts, e.g. variant T-cell epitopes may lead to different cellular
immune response [19,20]. Cellular immune responses directed to
variant M. tb epitopes may also be responsible for the observation
that mixed M. tb infections occur [21] and that TB patients are
prone to re-infections [22]. Only a limited number of M. tb strains
have been sequenced and most genetic variations appear to reside
in non-essential M. tb genes. This appears to be true for many M.
tb proteins, with the exception of the small immunogenic protein
Rv0288. This protein has the following identified naturally
occurring single amino acid exchanges: A10T, G13D, S27N and
A71S [23]. All of these substitutions are part of previously reported
CD8+ T-cell epitopes [17,24] and might therefore interfere either
with antigen presentation or subsequent T-cell recognition.
We chose to include 6 different M. tb-derived antigens in this
study, since M. tb proteins can be differentially expressed or
secreted during the course of infection. The immunodominant
secreted TB proteins Ag85B (Rv1886c) and ESAT-6 (Rv3875) are
part of several new TB vaccine candidates, [25,26,27]. They are
early targets of cellular immune responses, and expressed at
different time points of the infection, based on pre-clinical models
[28,29]. While Rv3875 (ESAT-6) is only expressed in M. tb and a
few other mycobacterial species (e.g. M. marinum and M. kansasii)
[30], Ag85B and TB10.4 (Rv0288), are, in addition to M. tb,
expressed in the Mycobacterium bovis derived vaccine strain bacillus
Calmette-Gue´rin (BCG) as well as in mycobacteria other than
tuberculosis. The non-secreted M. tb proteins, glycosyl transferase (1)
(Rv2958c), glycosyl transferase (2) (Rv2957) and cyclopropane-
fatty-acid synthase (CFA synthase) (Rv0447c) are predominantly
expressed in slow growing bacteria. They have previously been
identified from our group as targets for humoral and cell-mediated
immune responses [31,32,33]. These M. tb antigens are involved in
cellular metabolism [34,35,36] and are producing factors associ-
ated with resistance to macrophage mediated killing [37].
We report in this study the detailed mapping of M. tb peptides to
some of the most frequent MHC alleles in South Africa, their
impact on T-cell recognition and T-cell homing/differentiation
markers using a broad panel of M. tb MHC class I-peptide
multimers.
Materials and Methods
Recombinant proteins
The heavy and light chains of HLA-A*02:01, A*24:02,
A*30:01, A*30:02, A*68:01, B*07:02, B*58:01 and C*07:01 were
cloned into bacterial expression vectors (pET24d+ and pHN1).
The MHC molecules were produced as previously described
[8,38]; heavy and light chains were produced in Escherichia coli Bl21
DE3 pLys (Invitrogen, Carlsbad, California) as inclusion bodies,
they were purified, solubilized and folded to correct trimeric
structure in a pH 8.0 Tris-EDTA-arginine buffer (Sigma-Aldrich
Sweden AB, Stockholm, Sweden) together with allele-specific
candidate peptides (JPT Peptide Technologies GmbH, Berlin).
The peptides were: A*02:01 – FLPSDFFPSV (HBV CORE),
A*24:02 – RYLKDQQLL (HIV env), A*30:01 – KTKDIVNGL
(F-actin capping protein beta), A*30:02 – KIQNFRVYY (HIV-
integrase), A*68:01 – KTGGPIYKR (Influenza virus nucleopro-
tein), B*07:02 – TPRVTGGGAM (CMV pp65), B*58:01 –
IAMESIVIW (HIV RT) and C*07:01 – KYFDEHYEY (CDC28
protein). Correctly folded trimeric p-MHC-complexes were then
concentrated, biotinylated using the enzyme BirA (Avidity,
Aurora, USA) and affinity purified using an avidin column
(Thermo Fisher Scientific, Rockford, USA).
Peptide screening assay
96-well plates coated with biotinylated-bovine serum albumin
(BSA) and avidin (from BeckmanCoulter, San Diego, USA) were
used to immobilize 0.5 mg/ml biotinylated monomers. Overlap-
ping nonameric peptides (JPT Peptide Technologies GmbH,
Berlin, Germany) covering the three TB proteins TB10.4
(Rv0288), Ag85B (Rv1886c) and ESAT-6 (Rv3875) were used in
binding, affinity and off-rate studies as well as variant peptides
from Rv0288. The duplicated experiments were performed as
previously described [39,40], shortly; the monomer-coated plates
were stripped of the placeholder peptide leaving the heavy chain
free to re-associate with an added candidate peptide after addition
of b2-microglobulin. Positive binding was detected using a
fluorescent labeled conformation-dependent antibody (A*30;
IgM, clone 0273HA [One Lambda Inc, Canoga Park, USA],
A*02, A*24, A*68, B*07, B*58 and C*07; fluorescein isothiocy-
anate (FITC)-conjugated anti-HLA-A, -B and –C [BeckmanCoul-
ter, San Diego, USA]). The binding of each candidate peptide was
compared to the binding of an appropriate control peptide (same
peptides as used to produce the monomers, listed above). For
selected peptides further characterization of the binding were
made using affinity and off-rate assays. Affinity was measured by
incubating titrated peptide concentrations (1024 to 1029 M) on
the MHC coated 96-well plates in a manner similar to the binding
assay. An ED50 value, i.e. the peptide quantity needed to achieve
50% binding saturation was calculated. By incubating the
candidate peptide for different time points (0, 0.5 h, 1 h, 1.5 h,
2 h, 4 h, 6 h and 8 h), the stability of the p-MHC complexes could
be assessed as a t1/2 value, which is defined as the time point when
50% of the initial peptide concentration has dissociated from the
HLA-peptide molecule complexes. The binding, affinity, and off-
rate-values were calculated using the iTopiaTM System Software
(BeckmanCoulter, San Diego, USA). Sigmoidal dose response
curves were generated using PrismH 4.0 (GraphPad).
MHC Alleles Determine the CD8+ TB Response
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Selection of epitopes for multimer construction
Based on the data generated in the peptide binding assays,
previously reported data [17,24,40,41,42], or high SYFPEITHI
score [43], a set of 48 multimers covering epitopes from the TB
proteins Rv0288, Rv1886c, Rv3875, Rv2957, Rv2958c and
Rv0447c were obtained from BeckmanCoulter, San Diego,
USA; from Immudex, Copenhagen, Denmark or produced in
our lab as previously described [8].
Patient data
27 patients diagnosed with active pulmonary TB (prior to any
treatment), diagnosed with at least two positive sputum smears for
acid-fast bacilli or positive sputum culture for M. tb were enrolled
at the University of Stellenbosch, Cape Town and at the Pretoria
Academic Hospital in South Africa. Demographic data of the
patients are provided in Table S1. Peripheral blood mononuclear
cells (PBMCs) were separated at each location after informed
consent. The participants provided their written consent to
participate in this study and these documents are on file at the
clinical sites with the PI. The written consent forms were also
submitted to the respective ethical committees and were approved.
The institutional review boards (reference no. 45/2008, Faculty of
Health Sciences, University of Pretoria, South Africa and no.
N05/11/187, Health research and Ethics Committee, Stellen-
bosch University) approved the study. Frozen PBMCs were
shipped to Sweden and HLA-typed using sequence-specific primer
(SSP) typing kits (One Lambda Inc. Canoga Park, USA). Ethical
consent from the ethical committee in Stockholm (ref. 2011/863-
31/2) was acquired prior to sample analysis.
Cellular analysis with multimers
Freshly thawed PBMCs were incubated with MHC class I
multimers for 30 min at 37uC. Multimer positive events were
recorded in the CD3+CD8+CD42 compartment using the
following antibodies: anti-CD3-phycoerytin (PE)/Texas red
(ECD) (clone: UCHT1) (BeckmanCoulter, San Diego, USA),
anti-CD8a- allophycocyanin (APC)/Cy7 (clone: SK1) (Becton
Dickinson, Franklin Lakes, USA) and anti-CD4-Pacific orange
(clone: S3.5) (Invitrogen, Carlsbad, USA). The multimers were
fluorescently labeled with streptavidin-PE, streptavidin-APC and
fluorescein isothiocyanate (FITC). Cells in the CD3+CD82CD4+
compartment were excluded from enumeration of
CD3+CD8+multimer+ events. All cellular analyses were per-
formed using a FACS Gallios flow-cytometer (BeckmanCoulter,
San Diego, USA). Only multimer responses at least at least three
times higher than the negative control and for which we could
detect more than 50 events were further analyzed.
Phenotypic analysis of the T-cells
Phenotypic analysis of antigen-specific cells was performed
using the following Abs: anti-CD45RA-PerCP/Cy5.5 (Clone
HI100) (Biolegend, San Diego, USA) and anti-CCR7-PE/Cy7
(Clone 3D12) (Becton Dickinson, Franklin Lakes, USA). Anti-
CD107a-Pacific blue (PB) (clone: H4A3) (Biolegend, San Diego,
USA) was used as a degranulation marker and analysis of IL-7Ra
(alpha chain of the IL-7R) was performed using anti-CD127 APC/
Alexa-700 (clone: R34.34) (BeckmanCoulter, San Diego, USA).
Statistics
Statistical significance between different T-cell populations was
evaluated using PrismH 4.0 (GraphPad Software, La Jolla, USA)
using a Student’s two-sided t-test.
Results
Peptide-MHC binding analysis – epitope identification
Overlapping peptides covering the amino acid sequences of the
M. tb proteins Rv1886c (Ag85B) (n = 260) and Rv3875 (ESAT-6)
(n = 87) were used to study individual peptide binding to 5 HLA-A
MHC class I molecules (A*02:01, A*24:02, A*30:01, A*30:02 and
A*68:01), 2 HLA-B alleles (B*07:02 and B*58:01) and 1 HLA-C
allele (C*07:01). Peptides from Rv0288 (TB10.4) (n = 88) were
used to study peptide binding to previously non-reported MHC
class I alleles (HLA-A*68:01, B*58:01 and C*07:01). Peptides were
regarded as positive binders if the binding exceeded .40% of the
respective positive control peptide. In total, we could identify 361
MHC class I binding epitopes in the three proteins (Ag85B,
TB10.4 and ESAT-6), of which 92% were previously not reported.
68 epitopes were associated with A*02:01, 43 associated with
A*24:02, 8 with A*30:01, 99 with A*30:02, 43 with A*68:01, 25
with B*07:02, 45 with B*58:01 and 30 with C*07:01. In total,
A*30:02 had the highest binding frequency (27%) followed by
A*02:01 (19%), A*24:02 (12%), A*68:01 (12%), B*58:01 (12%),
C*07:01 (8%), B*07:02 (7%) and A*30:01 (2%).
For Rv3875, we could identify 40 binding epitopes, of which
more than half were associated with HLA-A*30:02 (n = 21),
followed by A*02:01 (n = 11), A*68:01 (n = 3), A*24:02 (n = 2),
B*58:01 (n = 2) and C*07:01 (n = 1). We were not able to identify
any epitopes from Rv3875 binding to the alleles A*30:01 and
B*07:02. In total, 34 peptides (39%) bound to at least one HLA
allele and most of the binding peptides were located in the middle
of the protein (Table 1).
For the much larger M. tb protein Rv1886c, 292 epitopes could
be identified associating with the following alleles: A*02:01
(n = 57), A*24:02 (n = 41), A*30:01 (n = 8), A*30:02 (n = 78),
A*68:01 (n = 29), B*07:02 (n = 25), B*58:01 (n = 29) and
C*07:01 (n = 25). The epitopes were scattered throughout the
amino acid sequence with some clustering of promiscuous epitopes
in the middle. 155 peptides (60%) bound to at least one MHC class
I allele; 75 epitopes were found to be promiscuous, i.e. binding to
more than one MHC class I allele. Some were highly promiscuous
and cross-binding to 7 out of 8 MHC class I alleles
(VANNTRLWV [Rv1886c241–249] [A*02:01, A*24:02, A*30:01,
A*30:02, B*07:02, B*58:01 and C*07:01]) or 6 out of 8
(KLVANNTRL [Rv1886c239–247] [A*02:01, A*24:02, A*30:01,
A*30:02, B*07:02 and B*58:01]) (Figure 1 and Table S2).
In addition, we could identify 29 binding epitopes from Rv0288
associating with A*68:01 (n = 11), B*58:01 (n = 14) and C*07:01
(n = 4) (Table 2). We also wanted to elucidate the effect of naturally
occurring single amino acid substitutions within these epitopes
concerning the binding to different MHC class I molecules. The
reported substitutions were part of 18 previously identified binding
epitopes (from the sequence of H37Rv) and we compared the
binding-rate of these M. tb epitopes to 24 novel epitopes which
were constructed including one or two amino acid substitutions
(Table 3). The variant epitope showed better MHC class I-binding
as compared to the reference epitopes in only 13% of the tested
peptide-MHC binding combinations. All of these were restricted
by ‘promiscuous alleles’ like HLA-A*02:01, A*24:02 and A*30:02.
Changing a binding epitope restricted by alleles with intermediate
(A*68:01 and B*58:01) or a more restricted binding pattern
(A*30:01, B*07:02 and C*07:01) resulted in a profound decrease
of peptide binding or even total abrogated MHC class I-peptide
binding.
MHC Alleles Determine the CD8+ TB Response
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Analysis of the nature of the p-MHC binding
Next, we analyzed in greater detail the Rv3875 epitopes that
bound with more than 50% to the respective MHC class I test
molecules as compared to the positive control peptide (30
epitopes). The nature of peptide binding to an MHC class I
molecule can be divided into affinity, i.e. the binding strength
between the peptide and the MHC molecule, and the dissociation
rate, i.e. the off-rate (t1/2) of the peptide-MHC complex. The
affinity ranged between 1 mM and 5 nM with the majority of the
peptides exhibiting an affinity in the lower end of the interval. The
dissociation rate ranged between 0.2 h and 4.9 h; both extremes
applied for HLA-A*02:01 (Table 1).
Since we identified a considerable number of binding epitopes
from the protein Rv1886c, we analyzed the binding characteristics
of only a selected set of peptides. The peptides were chosen based
on 1) not being previously reported, 2) high binding compared to
the positive control and 3) promiscuity (i.e. binding to several
MHC molecules). In total, we analyzed affinity and dissociation
rate from 121 novel M. tb candidate epitopes. The affinity ranged
between 400 mM and 5 nM with the majority between 9 mM and
10 nM. Some of the peptides showed a very rapid dissociation rate
(,0.1 h), while some formed a stable MHC class I-peptide
complex for up to 8 hours. We identified a high range of intra-
allelic differences (different peptides bound different to the same
HLA allele) as well as inter-allelic differences (same peptides bound
different to different alleles). The peptides bound generally in a
more stable fashion to the HLA-A alleles as compared to the B and
C alleles , with the exception of HLA-A*30:01 which exhibited an
off-rate of less than 1 h. Also, peptides binding to alleles with a
limited set of binding epitopes tended to dissociate more rapidly
(Table S2).
We identified in total 29 novel epitopes from the protein
Rv0288 binding to the alleles HLA-A*6801, B*58:01 and C*07:01
and analyzed the binding characteristics for the entire peptide set.
The affinity ranged between 700 mM and 30 nM, and the off-rate
between 0.1 h and 6 h. We could not see any specific inter- or
intra-allelic differences regarding affinity but we could detect a
very rapid dissociation rate of less than 20 minutes regarding all
candidate epitopes binding to C*07:01 (Table 2).
Alterations in individual amino acids lead to an increased or
decreased binding strength in an almost equal number of cases.
However we were only able to measure affinity in 20 out of 53
cases due to that too low MHC-peptide binding makes it
impossible to reliably study affinity and off-rate. This was the
case for all the variant epitopes restricted by A*30:01, A*68:01,
B*07:02 and C*07:01. In most cases, where the peptide variation
resulted in increased affinity, it increased the total peptide binding.
In cases where the MHC class I-peptide stability increased, the
increase was only marginal. In general, the amino acid exchange
lead to decreased MHC binding that could be explained by either
a decrease in 1) binding strength and/or 2) stability of the MHC
class I/peptide complex. However, a few outliers were identified
for which we could see an increase in both parameters (binding
strength and affinity) while the total peptide binding decreased,
e.g. HSMSSTHEA (Rv028870–78) to A*30:02 and
MLDHAGDMA (Rv028811–19) to A*02:01.
Multimeric analysis of selected TB epitopes
A*02, A*24, A*30 A*68, B*07, B*58 and C*07 belong to the
most prevalent MHC class I alleles in a South African population.
Therefore, we constructed 33 different multimers from the M. tb
proteins ESAT-6 (Rv3875), Ag85B (Rv1886c) and TB10.4
(Rv0288) as well as 12 multimers from other (non-secreted)
M. tb antigens (e.g. glycosyl transferase 1 [Rv2958c], glycosyl
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transferase 2 [Rv2957] and CFA synthase [Rv0447c]) with the
intention to evaluate the frequency, phenotype and functionality of
antigen-specific T-cells. MHC-peptide multimers were used to
enumerate CD8+ T-cell responses in blood from 27 patients
diagnosed with active pulmonary TB in South Africa. Examples of
staining and the gating strategy are provided in Figures S1 and S2.
The number of antigen-specific T-cell frequencies ranged
between 0 and 3.9% in the CD8+ T-cell population, with an
Figure 1. Alignment of the major histocompatibility complex (MHC) class I-binding epitopes with the amino acid sequence of
Rv1886c. Epitopes identified for HLA-A*02:01 are shown in light blue, for A*24:02 in dark blue, for A*30:01 in dark green, peptides for A*30:02 in
light green, for A*68:01 in yellow, for B*07:02 in orange, for B*58:01 in brown and for C*07:01 in red. Alignments of MHC class II restricted epitopes
(HLA-DR1 – dark grey, DR2 – medium grey and DR4 – light grey) that have previously been reported in reference [32] are included as well. The signal
sequence of Rv1886c is shown in red and the rest of the protein in black.
doi:10.1371/journal.pone.0058309.g001
Table 2. MHC class I binding, affinity and off-rate data for peptide-epitopes derived from Rv0288 (TB10.4).
A*68:01 B*58:01 C*07:01
Peptide ID Sequence* Bind** Aff O-rate Bind Aff O-rate Bind Aff O-rate
Rv02881–9 MSQIMYNYP 29 57 4E-06 1.1 10
Rv02884–12 IMYNYPAML 0 110 2E-07 1.0 67 2E-07 0.2
Rv02886–14 YNYPAMLGH 30 0 48 7E-06 0.3
Rv028835–43 EQAALQSAW 47 1E-05 2.8 79 6E-06 0.8 0
Rv028836–44 QAALQSAWQ 17 62 5E-05 0.5 7
Rv028841–49 SAWQGDTGI 30 46 3E-08 0.6 12
Rv028843–51 WQGDTGITY 61 1E-05 6.0 33 8E-06 1.8 0
Rv028846–54 DTGITYQAW 7 41 1E-06 2.3 0
Rv028847–55 TGITYQAWQ 8 40 4E-06 0.8 0
Rv028848–56 GITYQAWQA 0 46 9E-08 0.2 0
Rv028849–57 ITYQAWQAQ 56 9E-06 1.9 78 2E-07 0.5 0
Rv028850–58 TYQAWQAQW 0 119 1E-07 1.0 0
Rv028851–59 YQAWQAQWN 23 52 2E-06 2.0 0
Rv028852–60 QAWQAQWNQ 55 7E-06 3.0 45 4E-06 0.5 0
Rv028861–69 AMEDLVRAY 0 14 46 5E-06 0.1
Rv028866–74 VRAYHAMSS 29 10 79 1E-06 0.2
Rv028870–78 HAMSSTHEA 77 6E-06 0.5 16 6
Rv028873–81 SSTHEANTM 0 41 2E-06 0.8 7
Rv028877–85 EANTMAMMA 83 7E-04 1.9 0 3
Rv028878–86 ANTMAMMAR 147 3E-06 2.4 0 12
Rv028879–87 NTMAMMARD 67 7E-05 2.3 0 0
Rv028880–88 TMAMMARDT 47 6E-05 2.7 0 0
Rv028881–89 MAMMARDTA 96 5E-06 2.0 23 19
Rv028886–94 RDTAEAAKW 65 1E-05 4.3 45 5E-06 2.6 0
*Promiscuous epitopes are marked in italic. **Positive binding epitopes are marked in bold. Binding is reported as percent relative the binding of a positive control
peptide, affinity is reported as an ED50 value (M), and off-rate is reported as a t1/2 value (h), as described in material and methods. MHC class I-peptide complexes were
constructed for the epitopes: A68-Rv0288HAMSSTHEA and A68-Rv0288ANTMAMMAR.
doi:10.1371/journal.pone.0058309.t002
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average frequency of 0.3% multimer-reactive T-cells in CD8+ T-
cells. We were able to identify inter-epitope specific variations that
could be divided into 3 groups based on recognition frequencies.
The first group included epitopes that were almost never
recognized above the negative control multimer (e.g. A2-
Rv0447cVLAGSVDEL, A3001-Rv1886cVANNTRLWV and A3002-
Rv1886cVANNTRLWV). The second group constituted epitopes
for which we could detect specific T-cells only in some patients
(e.g. A2-Rv3875LLDEGKQSL, A24-Rv2958cKYIAADRKI and B58-
Rv1886cQTYKWETFL). The third group contained epitopes
that were recognized in blood from all patients (e.g. A2-
1886cKLVANNTRL, A24-Rv3875ELNNALQNL and A3002-
Rv0288QIMYNYPAM) (Figure 2A and Table S3). Based on the
construction of several different allele-specific multimers (e.g. 11
for HLA-A*02, 10 for HLA-A*24 and 11 for HLA-A*30), we
could identify differences in the allele-specific repertoires. Some
epitopes were never recognized by T-cells in any individuals, while
others were recognized in PBMCs from all patients, such as the
A*02-restricted epitope KLVANNTRL from Rv1886c, indicating
immunodominance (Figure S3).
We could also detect general allele-specific variations in the
detection of antigen-specific T-cells. Rv3875 epitopes were, for
example, generally recognized very strongly by A*24-restricted T-
cells, due to the high frequent recognition of the immunodominant
epitope Rv3875ELNNALQNL. On the other hand, Rv2957 derived
epitopes were not recognized in blood from HLA-A*02 and A*68
positive individuals at least the single epitope included in this study
derived from this protein (Figure 2B).
Since we managed to produce 6 different multimers presenting
the M. tb variant epitope (QI)MYNYPAM(LG), we were also able
to examine the nature of antigen-specific T-cell recognition of
‘MHC-promiscuous epitopes’. We could not detect significant
differences in the detection of antigen-specific T-cells, neither
inter-allelic, i.e. if the same epitope IMYNYPAML was presented
via the different HLA alleles (e.g. A*02, A*24 and A*30:02), nor
intra-allelic when the almost identical epitopes was restricted by
the same allele, e.g. A*24 (IMYNYPAML), MYNYPAMLG [0.3–
0.4%]), and A*30:02 (QIMYNYPAM and IMYNYPAML [0.3–
0.4%]). These data may suggest non-allele-specific T-cell recog-
nition of ‘promiscuous epitopes’ like (I)MYNYPAML(G)
(Figure 2C and Table S3), at least in the study population
examined in this report.
Phenotypic analysis of antigen-specific T-cells
Since we detected differences in epitope/antigen recognition
based on the restricting MHC class I allele and in the numbers of
antigen-specific T-cells, we proceeded to analyze the phenotype of
M. tb antigen-specific cells. The phenotype of CD8+ T-cells can be
defined by the cell-surface markers CD45RA and CCR7 [44,45].
The phenotype frequency analysis revealed that precursor
(CD45RA+CCR7+), effector memory (CD45RA2CCR72) and
terminally differentiated (CD45RA+CCR72) are almost equally
distributed (,30% in each population), while the average
percentage of central memory cells (CD45RA2CCR7+) was
around 6%. On the other hand, we detected a significantly higher
number of antigen-specific CD8+ T-cells in the precursor
compartment (45%) (p = 0.01) as well as a lower frequency of
cells in the effector memory compartment (21%) (p = 0.002)
(Figure 3A).
We were able to detect allele-specific differences concerning T-
cell maturation and differentiation. The HLA-A*30-restricted
(M. tb specific) T-cells were found, to a higher extent, in the
terminally differentiated effector compartment (p = 0.02) as
compared to the other HLA-A restricted antigen-specific T-cells.
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A similar trend could be seen for the allele HLA-C*07 (Figure 3B).
For effector memory antigen-specific CD8+ T-cells, we could
detect an MHC class I allele family based difference with a
significantly higher proportion of T-cells restricted by the allele
HLA-B*07 and a similar trend for the other HLA-B alleles
included in this study, i.e. B*58 (Figure 3C). For the other two
phenotypic compartments (precursor and central memory T-cells),
we could also identify a trend towards allele-specific differences,
although none were significant (Figure S4) Comparison of
differences within the phenotype of antigen-specific CD8+ T-cell
between different M. tb proteins showed a profile independent of
the nature of the M. tb antigens included in this study (Figure S4)
and the same was found to be true for the different epitopes of the
Rv0288 hot-spot (QI)MYNYPAM(LG) (Figure S5): differences in
antigen-specific CD8+ T-cell maturation/differentiation were
associated with the restricting MHC allele, yet not the presented
M. tb epitope.
Analysis of degranulation and survival markers
We analyzed the degranulation marker CD107a (LAMP-1),
which correlates with the cytotoxic capacity of CD8+ T-cells. We
compared the frequency of total CD8+ T-cells and the M. tb
antigen-specific cells concerning CD107a expression and could
detect significantly higher frequencies of antigen-specific T-cells
Figure 2. Percentage multimer positive CD8+ T-cells divided into different compartments. (A) Percentage antigen-specific recognition of
the 45 individual multimers used in this study, each dot represents the staining in PBMCs from one patient and the different restricting alleles are
shown in different colors (HLA-A*02:01 – black, A*24:02 – red, A*30:01 – orange, A*30:02 – green, A*68:01 – blue, B*07:02 – purple, B*58:01 – pink and
C*07:01 – turquoise), each individual multimer within an allele is shown by different shapes of dots. (B) Average detection in all patients of antigen-
specific T-cells divided per antigenic protein and per restricting allele (A*02:01 – black squares, A*24:02 – red triangles, A*30:01/A*30:02 – green
triangles, A*68:01 – blue diamonds, B*07:02 – purple circles, B*58:01 – pink crosses and C*07:01 – turquoise crosses). (C) Individual detection of
antigen-specific T-cells specific for the ‘super-epitope’ (QI)MYNYPAM(LG), each dot represents the staining in an individual patient, different colors
represents the different restricting allele (A*02:01 – black, A*24:02 – red, A*30:01 – orange and A*30:02 – green).
doi:10.1371/journal.pone.0058309.g002
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expressing the degranulation marker CD107a (4% vs. 19%,
p = 0.0005) (Figure 3D). The increase in CD107a expression was
independent of the restricting MHC allele and the nature of the M.
tb antigen and ranged from 5% (B*07) to 50% (A*68). M. tb
epitopes could be divided into 4 groups according to the frequency
of the antigen-specific CD8+ T-cells expressing CD107a. To the
first epitope group belonged T-cells with more than 70%
expressing CD107a, i.e. predominantly A*68 restricted epitopes.
The second group consisted of epitopes recognized by cells
expressing CD107a on 40–70% of the cells, i.e. mostly A*30-
restricted epitopes. The third group consisted of epitopes
recognized by cells expressing CD107a on 20–40% of the
antigen-specific T-cells, i.e. mostly A*30 and A*24 restricted
epitopes, and the rest belonged to the forth group. Generally, the
HLA-A*30 and A*68 restricted antigen-specific T-cells expressed
higher frequencies of CD107a (Figure 3E).
An important marker for T-cell survival is CD127 (IL-7
receptor a-chain). We were able to detect a significantly increased
Figure 3. Frequencies of total CD8+ T-cells as well as different compartments of antigen-specific CD8+ T-cells expressing
differentiation and maturation markers. (A) Total CD8+ T-cells (grey) vs. antigen-specific CD8+ T-cells (black) belonging to the different
phenotypic compartments; naı¨ve/precursor (CD45RA+CCR7+) (circles), central memory (CD45RA2CCR7+) (triangles), effector memory
(CD45RA2CCR72) (diamonds) and terminally differentiated cells (CD45RA+CCR72) (squares). (B) Total CD8+ and antigen-specific T-cells belonging
to the terminally differentiated compartment (CD45RA+CCR72) and (C) effector memory compartment (CD45RA2CCR72) divided per restricting
MHC class I allele (Total CD8+ T-cells – filled circles, A*02:01 – filled squares, A*24:02 – filled triangles, A*30:01/A*30:02 – filled diamonds, A*68:01 –
open circles, B*07:02 – open squares, B*58:01 – open triangles and C*07:01 – open diamonds). (D) Expression of the degranulation marker CD107a in
total CD8+ T-cells (grey) vs. antigen-specific CD8+ T-cells (black). (E) Total CD8+ and antigen-specific T-cells expressing CD107a divided per restricting
MHC class I allele (total CD8+ T-cells – filled circles, A*02:01 – filled squares, A*24:02 – filled triangles, A*30:01/A*30:02 – filled diamonds, A*68:01 –
open circles, B*07:02 – open squares, B*58:01 – open triangles and C*07:01 – open diamonds). (F) Expression of the survival marker CD127 in total
CD8+ T-cells (grey) vs. antigen-specific CD8+ T-cells (black). (G) Total CD8+ and antigen-specific T-cells expressing CD127 divided per restricting MHC
class I allele (total CD8+ T-cells – filled circles, A*02:01 – filled squares, A*24:02 – filled triangles, A*30:01/A*30:02 – filled diamonds, A*68:01 – open
circles, B*07:02 – open squares, B*58:01 – open triangles and C*07:01 – open diamonds). Each dot represents an individual multimer in one individual
TB patient. Student’s two-sided t-test was performed and significant values were calculated based on the following p-values: *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0058309.g003
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expression of this cell-surface marker on antigen-specific T-cells
(81%) as compared to the total CD8+ T-cells (69%) (p = 0.001)
(Figure 3F). This was also true for all MHC class I alleles
presenting M. tb epitopes to CD8+ T-cells, except B*07
(Figure 3G). Based on variations between epitope-derived M. tb
protein targets, we could neither detect difference regarding
expression of CD107a nor of CD127 (Figure S6). This was also
true when comparing the Rv0288 derived ‘super-epitope’ which
binds to a higher number of MHC class I molecules (QI)MYNY-
PAM(LG) (Figure S6) Also here, the expression of CD107a and
CD127 was closely associated with the MHC class I restricting
allele, and not the M. tb target protein.
Effect of amino acid substitutions on TCR recognition
An amino acid substitution within an epitope might abrogate or
profoundly change the interaction to a specific MHC class I allele.
However, the effect on TCR recognition is biologically equally
relevant. To be able to study TCR-MHC-class I peptide
interaction, we constructed 3 pairs of multimers consisting of a
wild-type M. tb target epitope (from H37Rv) and epitopes
containing one or two naturally occurring substitutions for the
alleles A*02 and A*24. The two epitopes binding to HLA-A*02
(AML(G/D)HAGDM and ML(G/D)HAGDMA) had the mutations
in the 3rd or the 4th amino acid potentially being part of the TCR
recognition site, while the epitope associating with A*24 (MYNYP(A/
T)ML(G/D)) contained two mutations in the 6th and 9th position (of
which the first position might affect TCR recognition). Although the
association of these variant M. tb epitopes to its corresponding MHC
molecule had either no effect, or showed decreased MHC binding,
multimers containing these M. tb variant epitopes showed a tendency
of detecting a higher frequency of antigen-specific T-cells as
compared to multimers presenting the wild-type epitopes
(A2AML(G/D)HAGDM 0.12/0.20%, A2ML(G/D)HAGDMA 0.13/0.25%
and A24MYNYP(A/T)ML(G/D) 0.44/0.51%) (Figure 4A). Next, we tested
whether the wild type and the variant epitope were recognized by the
same or different T-cell population(s). This was possible by co-
staining PBMCs with two separate multimers presenting the
reference and variant epitope labeled with different fluorochromes.
The results clearly showed that two different antigen-specific T-cell
populations recognized the wild type and the variant M. tb epitope
(Figure 4B).
Biochemical factors influencing antigen-specific T-cell
recognition
Previous data suggested correlations between high MHC class I-
peptide affinity and dominant T-cell responses [46]. We compared
therefore the binding characteristics of the p-MHC complex with
the actual frequency of antigen-specific T-cells recognizing a
specific epitope. Based on our data concerning affinity, dissocia-
tion rate and M. tb epitope-specific recognition frequencies, it was
possible to determine that among the 7 epitopes, which showed the
highest average antigen-specific recognition (.0.4%), the affinity
varied considerably (between 6 mM and 8 nM), as well as the off-
rate (0.5 h–27 h). In addition, we could detect allele-specific
characteristics such as very high affinity regarding all the HLA-
A*30 restricted epitopes and the opposite was found to be true
regarding the B*07 restricted epitopes. However, this did not
correlate with the frequency of antigen-specific CD8+ T-cells (in
PBMCs from patients with active TB). The highest frequency of
M. tb-specific T-cells for almost all epitopes was restricted by HLA-
A*24 (Figure 5).
Discussion
Our study shows that, at all three levels (MHC binding, T-cell-
recognition and the nature of the specific T-cells), we were able to
detect allele-specific differences which potentially affect CD8+ T-
cell immune-recognition. Regarding the p-MHC associations, we
were able to confirm a broad peptide-binding repertoire for some
alleles (e.g. HLA-A*02:01, A*24:02 and A*30:02) and a more
restricted peptide-binding repertoire for other alleles (e.g. A*30:01
and B*07:02). This is in line with previously reported data (yet
with different peptide ligands) [17,24,39,47]. In addition, we
included the less well studied alleles A*68:01 and B*58:01 as well
as the (not yet reported) allele C*07:01. A*68:01 and B*58:01
showed a relatively broad binding repertoire, while C*07:01
Figure 4. Antigen-specific recognition of the immunogenic
epitopes from the H37Rv reference strain as well as the same
epitopes containing naturally occurring amino acid substitu-
tions. (A) Percent antigen specific CD8+ T-cell recognizing the A*02:01
restricted epitopes (AML(G/D)HAGDM) (circles) and (ML(G/D)HAGDMA)
(squares) and the A*24:02 restricted epitope (MYNYP(A/T)ML(G/D)
(diamonds), wild-type epitopes (closed symbols) and variant epitopes
(open symbols). (B) Representative figures of multimer staining
regarding the A*24:02 restricted epitope (MYNYP(A/T)ML(G/D)). The
x-axis shows the staining of the wt epitope and the y-axis staining the
variant epitopes. Numbers of events for the wt/mut epitopes regarding
patient 6088 were +– 162, –+ 181 and ++ 2. A similar T-cell distribution
could be detected regarding patient 5905 (+– 17, –+ 21 and ++ 1).
doi:10.1371/journal.pone.0058309.g004
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showed a very restricted peptide binding. Structural constrains,
electrostatic charge and hydrophobicity within the MHC binding
pockets dictate the binding peptide repertoire [48] and are
therefore part of the explanation why inter-allelic differences can
be seen in the broadness of the peptide binding repertoires. In
addition, these factors influence the stability of the p-MHC
complex and might therefore explain some of the inter-allelic
differences that could be seen in affinity and peptide dissociation
rates.
The stability and off-rate are factors that are biologically
important; they determine the time frame in which a certain
epitope would be available for T-cell priming and for recognition
in the effector phase of the immune response. The allele-specific
differences in the p-MHC dissociation rate probably originate
from intrinsic structural features of the allotype. This would imply
that not only a limited number of epitopes would be available for
presentation by these alleles but also that the time-frame in which
the presentation could occur would be shorter. This scenario
might entail a disadvantage for immune-recognition in individuals
with certain allotypes, yet a fast peptide off-rate seems to be able to
be counter-balanced by a high affinity, as shown for a number of
M. tb epitopes included in this study. Affinities (ED50) between
100 mM and 10 nM have previously been identified using a similar
experimental design and our findings in this study are in line with
these data [24,39].
We identified highly promiscuous ‘hot-spots’ in M. tb proteins of
inter-allelic binding such as Rv1886c [(KL)VANNTRL(WV) and
(L)AAYHPQQF(I)] and Rv0288 [(QI)MYNYPAM(LG)], adding
more alleles to the already identified hotspot in this protein
[17,24]. For some epitopes, promiscuous binding to up to 7
different HLA class I alleles including members of both HLA-A, B
and C allele families have been identified in this study. In addition,
some of these areas have previously been shown to be able to bind
to the MHC class II alleles DR1, DR2 and DR4 [32]. We have
also been able to show allele-independent T-cell recognition for
the Rv0288 derived epitope between five different HLA-A alleles.
Since the individual T-cell responses were found to be similar,
concerning T-cell frequency, T-cell phenotype and effector
functions, these immunological ‘hot-spots’ might be potential
candidates for peptide-based vaccine-strategies since the allelic
coverage would include a large part of the world population,
including the most common HLA-A allele in Caucasians (A*02), in
Asians (A*24) and in Africans (A*30) [9].
Even though the importance of different MHC class I allotypes
in shaping the possible peptide-repertoires is well established, we
know in fact very little about how inter-allelic variations affect the
generation, phenotype and functionality of a pathogen-specific T-
cell repertoire. The immune-recognition by antigen-specific CD8+
T-cells in many diseases is often directed against a few of the many
potential epitopes originating from a complex pathogen. This
‘skewing’ of the immune system gives rise to immune-dominant
epitopes, which might be accompanied by less recognized sub-
dominant epitopes [49]. The driving force behind immune-
dominance and sub-dominance in different disease settings is not
completely understood, but availability (time and receptor
numbers) of a certain p-MHC complex on the cell-surface [50],
as well as conformation of the epitope presented [51] and
frequencies of T-cells precursors with the possibility of recognizing
the epitope [52] seem to be crucial factors in this process. In this
study, we were able to detect a dominant response in blood from
some patients, for instance against the A*24 restricted Rv3875
epitope ELNNALQNL. This is interesting, since the majority of
previously described dominant M. tb. epitopes seem to be HLA-B
restricted [24,53]. However, T-cell immune-dominance concern-
ing a single epitope seems to be quite rare in active M. tb infection,
since the mapping using 48 different multimers (some were
previously described [17,24,40,41,54]) has not revealed a single
dominant CD8+ T-cell epitope, yet a low frequency of a broad
panel of co-dominant M. tb epitopes in the peripheral circulation
of most patients infected with M. tb. The dominance and the
immunological profile might however differ between the site of
infection and the peripheral blood cells used in this study, as
previously reported [42].
The generation of a broader T-cell repertoire may protect from
the emergence of escape mutations in viral disease. A broader T-
cell repertoire targeting ‘subdominant’ epitope may not be
associated with clinical efficacy in TB, since these samples were
taken from patients who failed to contain their disease (all
individuals in the current study exhibited active pulmonary
disease). This seems to be more in line with the low frequency
of disease-reactive T-cells in the peripheral circulation that
previously has been seen in the context of cancer [55] or the
Figure 5. Heat-map comparing epitope-MHC affinity, epitope-
MHC dissociation rate and antigen-specific CD8+ T-cell recog-
nition. The affinity was divided into the following groups ,10 nM
(dark red), 10–70 nM (light red), 70–500 nM (orange), 500–1000 nM
(dark yellow) and .1 mM (light yellow). The dissociation-rate (off-rate)
were divided according to .10 h (dark red), 6–10 h (light red), 3–6 h
(orange), 1.5–3 h (dark yellow) and ,1.5 h (light yellow). Finally, the T-
cell recognition was grouped as follows; .1% antigen-specific CD8+ T-
cells recognizing the epitope (dark red), 0.6–1% (light red), 0.4–0.6%
(orange), 0.2–0.4% (dark yellow) and ,0.2% (light yellow).
doi:10.1371/journal.pone.0058309.g005
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loss of certain immune-dominant epitopes in the peripheral
circulation in chronic infection with simian immunodeficiency
virus (SIV). Future studies will show, whether dominant T-cell
responses arise after effective TB treatment, whether such immune
responses are associated with latent TB, which represents a broad
clinical spectrum, or even with continuous exposure to M. tb.
Deciphering the phenotype of antigen-specific CD8+ T-cells is
important in the context of memory formation as well as for
immune effector functions [44,45]. Previous studies have identified
the majority of antigen-specific T-cells residing in memory
(CD45RA2) [40,56] or terminally differentiated
(CD45RA+CCR72) [41] T-cells. Yet, an increasing number of
studies identified a majority of M. tb-specific or BCG-reactive T-
cells in both adults and children belonging to ‘naı¨ve’/precursor
(CD45RA+CCR7+)/(CD45RA+CD28+) [17,57,58,59] compart-
ment. In this study, we were once again able to detect that the
majority of M. tb antigen-specific T-cells resides in the
(CD45RA+CCR7+) precursor population – in contrast to the
phenotype of total CD8+ T-cells which showed equal number of
naı¨ve, effector memory and terminally differentiated cells. It has
previously been speculated for HIV infection, where this
phenomenon also has been observed, that the antigen-specific
T-cells with cell-surface expression of both CD45RA and CCR7
might represent effector memory cells that reverted back to a
‘naı¨ve’ like phenotype without losing this subset’s ability of
proliferation upon antigen-stimulation [45], yet it may also be
due to increased lymphopoiesis in patients with active TB.
We detected allele-specific variations, rather than antigen-
specific, regarding frequencies and the differentiation/maturation
profile (based on CD45RA/CCR7) of antigen-specific T-cells.
First, we hypothesized that this finding was due to differences in
the presented M. tb epitope and thus due to the nature of the target
protein, since the promiscuous epitopes were similarly recognized
by inter-allelic restricted T-cells. However, when we compared
several different epitopes, restricted by the same allele, allele-
specific patterns of immune-recognition emerged while the
antigen-specific patterns were remarkably constant. This was in
contrast to the levels of vaccine-induced antigen-specific T-cells
which were found to be higher targeting epitopes originating from
Rv1886c (compared to Rv0288) in one previous study [25], it was
also in contrast to the different phenotype of antigen-specific cells
found in another study [41]. However, the immune-profile of
active TB disease and the vaccine-induced profile might not
correlate, and in the second study the phenotypic profile of only a
single epitope/protein was compared.
To our knowledge, no correlations between the T-cell profile
and the restricting allele have been shown before in TB. One
example has been reported in HIV infection where some alleles
like B*57 and B*58, that have been associated with ‘elite
controllers’, associated with higher numbers of specific cytokine
producing cells [60]. Interestingly, the prevalent African alleles
HLA-A*30 and C*07 restricted epitopes give rise to higher
proportions of terminally differentiated effector CD8+ T-cells in
African TB patients and this T-cell phenotype has been shown to
be important in controlling the disease [3]. One possible
explanation is that the long-standing co-evolution between
mycobacteria and humans has taken part in the regional selection
of the most prevalent MHC class I alleles based on an advantage
in CD8+ T-cell responses, i.e. to expand immune effector T-cells.
In line with this observation is also the fact that these alleles seem
to restrict M. tb antigen specific T-cells with high CD107a
expression ex vivo (indicating cytotoxic function).
We were able to detect biologically relevant differences
concerning the naturally occurring amino-acid substitutions in
the protein Rv0288. Since M. tb previously has been shown to
express low sequence variability in most of its epitopes, it was
speculated that some immune-recognition might be beneficial for
the bacteria, for instance in the establishment of a latent infection
or by contributing to transmission [23]. We have studied the effect
of the epitope-based polymorphism on both the MHC level as well
as on the TCR recognition level for the protein Rv0288. An
explanation for the higher frequency of amino acid substitutions in
this protein [23] (indicating immune-evasion) might be that most
of the substitutions are part of immunological hot-spots with broad
inter-allelic immune recognition [17,24]. We could show in the
current study that most of the substitutions affected MHC class I
binding negatively, indicating a potential loss of peptide presen-
tation. Some of the substitutions reside within an anchor residue of
the peptides and might therefore directly interfere with allele-
specific peptide-binding. On the other hand, explanations for the
negative effect of other substitutions might be that they cause steric
hindrance, or changes in intra-peptide constrains changing the
conformation of upward pointing residues [61]. The outcome of
individual p-MHC-TCRs interactions is determined by affinity
and avidity dictating positive and negative downstream signaling
events such as CD3 zeta-chain phosphorylation [62]. In this study,
we could still detect an epitope-specific antigen-specific T-cell
population after introducing the amino acid substitution, although
these T-cells were found to belong to a complete separate cell
population as compared to the T-cells recognizing the original
epitope. This change in TCR-repertoire usage upon amino acid
substitution in an epitope has previously been seen in SIV
infections [63] as well as within an influenza epitope restricted by
H2-Db [61]. It would be of interest to elucidate if these different T-
cell populations exhibit similar functionality showing a full or
partial agonistic, or even antagonistic, effect on the TCR
repertoire recognizing wild-type or variant M. tb epitopes.
In conclusion, we constructed a broad panel of novel tools to be
able to study M. tb-specific responses in African with TB infection.
We could detect a low frequency of a broad repertoire of co-
dominant M. tb epitopes in the peripheral circulation of patients
with active TB. The study of host-pathogen effects on immune-
recognition in M. tb derived CD8+ T-cell epitopes revealed 1)
MHC class I allele specific differences in the broadness of the
peptide-binding repertoire, 2) associations of the frequency and
phenotype of M. tb antigen-specific T-cells with the MHC class I
restricting alleles and 3) differences between variant M. tb epitopes
concerning peptide binding and T-cell recognition. This study
provides a first view of the nature of the anti-M. tb specific CD8+
response in patients with an African background. It is our hope
that these findings, as well as these novel tools will aid future
research on M. tb in Africa.
Supporting Information
Figure S1 Example of staining using the cell surface
markers CD3, CD4, CD8, multimer, CD45RA, CCR7,
CD107a and CD12 (PAT 1284 and PAT 3282) in African
TB patients. Numbers show the frequencies of cell positive for
the specific marker/markers. The gating strategy was the
following: Based on forward and side-scatter, lymphocytes were
detected. From the lymphocytes, T-cells were enumerated using
the CD3 marker. These cells were then divided into CD4+ T-cells
and CD8+ T-cells based on expression of CD4 and CD8. In the
CD8+ T-cells, multimer-specific cells as well as cells expressing the
cell surface markers CD45RA, CCR7, CD107a and CD127 were
detected. Finally, in the multimer positive cells the frequencies of
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cells expressing the markers CD45RA, CCR7, CD107a and
CD127 were detected as well.
(TIF)
Figure S2 Examples of positive and negative multimer
staining. The multimer specific cells were detected in the
CD3+CD8+ population using negative multimers and epitope
specific multimers presenting the following epitopes: FIYAGSLSA
(HLA-A*02:01), ELNNALQNL (A*24:02), QIMYNYPAM
(A*30:01 and A*30:02), HAMSSTHEA (A*68:01), IPKLVANNT
(B*07:02), QTYKWETFL (B*58:01) and ANNTRLWVY
(C*07:01). Numbers are indicating frequencies of multimer-
specific cells.
(TIF)
Figure S3 The antigen-specific recognition of the HLA-
A*02:01 (A) and A*30 (A*30:01 – open symbols and
A*30:02 – closed symbols) (B) restricted multimers, each
dot represents the individual staining in one patient, the
colors represents the M. tb protein and the derivative
epitope (Rv0288 – black, Rv1886c – red, Rv3875 – blue
and Rv2958c, Rv2957 and Rv0447c – green).
(TIF)
Figure S4 Frequency of total CD8+ and antigen-specific
T-cells belonging to the (A) naı¨ve compartment
(CD45RA+, CCR7+) and (B) central memory compart-
ment (CD45RA2, CCR7+) divided per restricting MHC
class I allele (Total CD8+ T-cells – filled circles, A*02:01
– filled squares, A*24:02 – filled triangles, A*30:01/
A*30:02 – filled diamonds, A*68:01 – open circles,
B*07:02 – open squares, B*58:01 – open triangles and
C*07:01 – open diamonds). Total CD8+ and antigen-specific
T-cells belonging to the (C) naı¨ve compartment (CD45RA+,
CCR7+), central memory compartment (D) (CD45RA2,
CCR7+), (E) effector memory compartment (CD45RA2,
CCR72) and (F) terminally differentiated compartment
(CD45RA+, CCR72) divided per immunogenic TB protein
(Total CD8+ T-cells – circles, Rv0288 – squares, Rv1886c –
triangles, Rv3875 – diamonds and antigens expressed primarily on
slow growing bacteria (Rv2958c, Rv2957 and Rv0447c -stars).
Each dot represents an individual tetramer in one individual TB
patient.
(TIF)
Figure S5 Frequency of total CD8+ T-cell belonging to
the (A) naı¨ve compartment (CD45RA+, CCR7+), (B)
central memory compartment (CD45RA2, CCR7+), (C)
effector memory compartment (CD45RA2, CCR72) and
(D) terminally differentiated compartment (CD45RA+,
CCR72) specific for the ‘super-epitope’ (QI)MYNY-
PAM(LG) (A*02:01-IMYNYPAML – black circles,
A*24:02-IMYNYPAML – dark grey circles, A*24:02-
MYNYPAMLG – dark grey squares, A*30:01-QIMYNY-
PAM – light grey triangles, A*30:02-QIMYNYPAM – open
triangles and A*30:02-IMYNYPAML – open circles). Each
dot represents an individual tetramer in one individual TB patient.
(TIF)
Figure S6 Frequency of total CD8+ and antigen-specific
T-cells expressing (A) CD107a and (B) CD127 divided
per epitope derived protein (Total CD8+ T-cells –
circles, Rv0288 – squares, Rv1886c – triangles, Rv3875
– diamonds) and antigens expressed primarily on slow
growing bacteria (Rv2958c, Rv2957 and Rv0447c – stars).
CD8+ T-cells expressing (C) CD107a and (D) CD127 specific for
the ‘super-epitope’ (QI)MYNYPAM(LG) (A*02:01-IMYNYPAML
– black circles, A*24:02-IMYNYPAML – dark grey circles,
A*24:02-MYNYPAMLG – dark grey squares, A*30:01-QIMY-
NYPAM – light grey triangles, A*30:02-QIMYNYPAM – open
triangles and A*30:02-IMYNYPAML – open circles). Each dot
represents an individual tetramer in one individual TB patient.
Each dot represents an individual tetramer in one individual TB
patient.
(TIF)
Table S1 Demographic data of the included patients.
(PDF)
Table S2 MHC class I binding affinity and off-rate data
for peptide-epitopes derived from Rv1886c (Ag85B).
(PDF)
Table S3 Frequency of epitope-specific T cells identi-
fied by multimer staining.
(PDF)
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